Key result
Guideline-directed medical therapy remains underutilized in HFrEF, with only ~1% simultaneously receiving target doses.
Why the study?
Guidelines recommend multiple medications for HFrEF, but the degree to which gaps in medication use and dosing persist in contemporary outpatient practice is unclear.
Observational (n=3,518)
Yes
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“We need to turn our thinking on its head about heart failure in clinical practice.”
“In HFrEF, the four medications clearly reduce all-cause mortality, are nonoverlapping and truly and fully additive, and their benefits are cumulative, incremental, and begin within days. Yet, when we look at their actual implementation in clinical practice, we've seen this slow and variable uptake.”
“Imagine for a moment that there is a deadly type of cancer that claims the lives of more than one-half a million Americans each year. Thankfully, there are well-tolerated therapies that offer a several-fold decrease in risk of mortality when taken together. One might expect widespread use of these treatments in patients who meet criteria, but national registry data show that only approximately 1% of the patients who qualify are prescribed appropriate doses of these therapies. It is likely that there would be public outrage and calls to action for initiatives aimed at urgent improvement. Clinicians and health care systems would be held accountable.”
There are significant gaps in the prescription and optimal dosing of guideline-directed medical therapy for HFrEF in contemporary US outpatient practice, with only 1% of eligible patients receiving target doses of all medication classes.
BACKGROUND Guidelines strongly recommend patients with heart failure with reduced ejection fraction (HFrEF) be treated with multiple medications proven to improve clinical outcomes, as tolerated. The degree to which gaps in medication use and dosing persist in contemporary outpatient practice is unclear. OBJECTIVES This study sought to characterize patterns and factors associated with use and dose of HFrEF medications in current practice. METHODS The CHAMP-HF (Change the Management of Patients with Heart Failure) registry included outpatients in the United States with chronic HFrEF receiving at least 1 oral medication for management of HF. Patients were characterized by baseline use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA). Patient-level factors associated with medication use were examined. RESULTS Overall, 3,518 patients from 150 primary care and cardiology practices were included. Mean age was 66 ± 13 years, 29% were female, and mean EF was 29 ± 8%. Among eligible patients, 27%, 33%, and 67% were not prescribed ACEI/ARB/ARNI, beta-blocker, and MRA therapy, respectively. When medications were prescribed, few patients were receiving target doses of ACEI/ARB (17%), ARNI (14%), and beta-blocker (28%), whereas most patients were receiving target doses of MRA therapy (77%). Among patients eligible for all classes of medication, 1% were simultaneously receiving target doses of ACE/ARB/ARNI, beta-blocker, and MRA. In adjusted models, older age, lower blood pressure, more severe functional class, renal insufficiency, and recent HF hospitalization generally favored lower medication utilization or dose. Social and economic characteristics were not independently associated with medication use or dose. CONCLUSIONS In this contemporary outpatient HFrEF registry, significant gaps in use and dose of guideline-directed medical therapy remain. Multiple clinical factors were associated with medication use and dose prescribed. Strategies to improve guideline-directed use of HFrEF medications remain urgently needed, and these findings may inform targeted approaches to optimize outpatient medical therapy.
No takes yet. Share an insight, caveat, or question.
Greene et al. (2018) conducted an observational in Heart failure with reduced ejection fraction (HFrEF) (n=3,518). Guideline-directed medical therapy (ACEI/ARB/ARNI, beta-blocker, and MRA) was evaluated on Use and dose of HFrEF medications. In a contemporary US registry of HFrEF outpatients, significant gaps in guideline-directed medical therapy remain, with only 1% of eligible patients simultaneously receiving target doses.
Synapse has enriched 10 related papers. Consider them for comparative context: